Dataset Information

Acute Ataxia and Myoclonus in COVID-19: A Case Series.

ABSTRACT:

SUBMITTER: Sundar US

PROVIDER: S-EPMC8680876 | biostudies-literature | 2021 Sep-Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Acute Ataxia and Myoclonus in COVID-19: A Case Series.

Sundar Uma S US Shah Meera H MH Merchant Sanah A SA Asole Dnyaneshwar C DC

Annals of Indian Academy of Neurology 20210416 5

PMID: 35002162

Similar Datasets

Project description:BackgroundIn accordance with the rising number of SARS-CoV‑2 infections, reports of neurological complications have also increased. They include cerebrovascular diseases but also immunological diseases such as Guillain-Barre syndrome (GBS), Miller-Fisher syndrome (MFS), and opsoclonus-myoclonus-ataxia syndrome (OMAS). While GBS and MFS are typical postinfectious complications, OMAS has only recently been described in the context of COVID-19. GBS, MFS, and OMAS can occur as para- and postinfectious, with different underlying pathomechanisms depending on the time of neurological symptom onset. The study aimed to describe clinical features, time between infection and onset of neurological symptoms, and outcome for these diseases.MethodsAll COVID-19 patients treated in the neurological ward between January 2020 and December 2022 were screened for GBS, MFS, and OMAS. The clinical features of all patients, with a particular focus on the time of onset of neurological symptoms, were analyzed.ResultsThis case series included 12 patients (7 GBS, 2 MFS, 3 OMAS). All GBS and one MFS patient received immunomodulatory treatment. Three patients (2 GBS, 1 OMAS) had a severe COVID-19 infection and received mechanical ventilation. In patients with OMAS, only one patient received treatment with intravenous immunoglobulin and cortisone. The remaining two patients, both with disease onset concurrent with SARS-COV‑2 infection, recovered swiftly without treatment. In all subgroups, patients with concurrent onset of neurological symptoms and COVID-19 infection showed a trend toward shorter disease duration.ConclusionAll patient groups displayed a shorter disease duration if the onset of neurological symptoms occurred shortly after the COVID-19 diagnosis. In particular, both the OMAS patients with symptom onset concurrent with COVID-19 showed only abortive symptoms followed by a swift recovery. This observation would suggest different pathomechanisms for immune-mediated diseases depending on the time of onset after an infection.

Dataset Information

Acute Ataxia and Myoclonus in COVID-19: A Case Series.

Publications

Acute Ataxia and Myoclonus in COVID-19: A Case Series.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets